Suppr超能文献

亚洲人群中 OAT3(SLC22A8)低频多态性导致头孢噻肟清除率降低。

Reduced renal clearance of cefotaxime in asians with a low-frequency polymorphism of OAT3 (SLC22A8).

机构信息

Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, California, USA.

出版信息

J Pharm Sci. 2013 Sep;102(9):3451-7. doi: 10.1002/jps.23581. Epub 2013 May 6.

Abstract

Organic anion transporter 3 (OAT3, SLC22A8), a transporter expressed on the basolateral membrane of the proximal tubule, plays a critical role in the renal excretion of organic anions including many therapeutic drugs. The goal of this study was to evaluate the in vivo effects of the OAT3-Ile305Phe variant (rs11568482), present at 3.5% allele frequency in Asians, on drug disposition with a focus on cefotaxime, a cephalosporin antibiotic. In HEK293-Flp-In cells, the OAT3-Ile305Phe variant had a lower maximum cefotaxime transport activity, Vmax , [159 ± 3 nmol*(mg protein)(-1) /min (mean ± SD)] compared with the reference OAT3 [305 ± 28 nmol*(mg protein)(-1) /min, (mean ± SD), p < 0.01], whereas the Michaelis-Menten constant values (Km ) did not differ. In healthy volunteers, we found volunteers that were heterozygous for the Ile305Phe variant and had a significantly lower cefotaxime renal clearance (CLR ; mean ± SD: 84.8 ± 32.1 mL/min, n = 5) compared with volunteers that were homozygous for the reference allele (158 ± 44.1 mL/min, n = 10; p = 0.006). Furthermore, the net secretory component of cefotaxime renal clearance (CLsec ) was reduced in volunteers heterozygous for the variant allele [33.3 ± 31.8 mL/min (mean ± SD)] compared with volunteers homozygous for the OAT3 reference allele [97.0 ± 42.2 mL/min (mean ± SD), p = 0.01]. In summary, our study suggests that a low-frequency reduced-function polymorphism of OAT3 associates with reduced cefotaxime CLR and CL(sec) .

摘要

有机阴离子转运体 3(OAT3,SLC22A8)是一种表达于近端肾小管基底外侧膜的转运体,在有机阴离子(包括许多治疗药物)的肾脏排泄中发挥关键作用。本研究的目的是评估亚洲人群中 3.5%等位基因频率的 OAT3-Ile305Phe 变体(rs11568482)对药物处置的体内影响,重点是头孢噻肟,一种头孢菌素类抗生素。在 HEK293-Flp-In 细胞中,OAT3-Ile305Phe 变体的头孢噻肟最大转运活性,Vmax,[159±3nmol*(mg 蛋白)-1/min(平均值±SD)]明显低于参考 OAT3[305±28nmol*(mg 蛋白)-1/min,(平均值±SD),p<0.01],而米氏常数(Km)值没有差异。在健康志愿者中,我们发现杂合子 Ile305Phe 变体的志愿者的头孢噻肟肾清除率(CLR;平均值±SD:84.8±32.1mL/min,n=5)明显低于参考等位基因纯合子的志愿者(158±44.1mL/min,n=10;p=0.006)。此外,头孢噻肟肾清除率(CLsec)的净分泌成分在杂合子变体等位基因的志愿者中降低[33.3±31.8mL/min(平均值±SD)],与 OAT3 参考等位基因纯合子的志愿者相比[97.0±42.2mL/min(平均值±SD),p=0.01]。总之,我们的研究表明,OAT3 的一个低频低功能多态性与头孢噻肟 CLR 和 CL(sec)降低相关。

相似文献

1
Reduced renal clearance of cefotaxime in asians with a low-frequency polymorphism of OAT3 (SLC22A8).
J Pharm Sci. 2013 Sep;102(9):3451-7. doi: 10.1002/jps.23581. Epub 2013 May 6.
3
Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes: consequences for pravastatin pharmacokinetics.
Clin Pharmacol Ther. 2003 Jun;73(6):554-65. doi: 10.1016/S0009-9236(03)00060-2.
4
The human organic anion transporter 3 (OAT3; SLC22A8): genetic variation and functional genomics.
Am J Physiol Renal Physiol. 2006 Apr;290(4):F905-12. doi: 10.1152/ajprenal.00272.2005. Epub 2005 Nov 15.
5
Differential interactions of the β-lactam cloxacillin with human renal organic anion transporters (OATs).
Fundam Clin Pharmacol. 2020 Aug;34(4):476-483. doi: 10.1111/fcp.12541. Epub 2020 Feb 25.
6
Organic anion transporter OAT3 enhances the glucosuric effect of the SGLT2 inhibitor empagliflozin.
Am J Physiol Renal Physiol. 2018 Aug 1;315(2):F386-F394. doi: 10.1152/ajprenal.00503.2017. Epub 2018 Feb 7.
8
Organic anion transporter 3 (Oat3/Slc22a8) knockout mice exhibit altered clearance and distribution of penicillin G.
Am J Physiol Renal Physiol. 2007 Oct;293(4):F1332-41. doi: 10.1152/ajprenal.00319.2007. Epub 2007 Aug 8.
10
Interaction of human organic anion transporters with various cephalosporin antibiotics.
Eur J Pharmacol. 2002 Mar 8;438(3):137-42. doi: 10.1016/s0014-2999(02)01306-7.

引用本文的文献

1
Physiologically Based Pharmacokinetic Model of Cefotaxime in Patients with Impaired Renal Function.
Clin Pharmacokinet. 2025 Feb;64(2):257-273. doi: 10.1007/s40262-024-01469-x. Epub 2025 Jan 7.
3
.
Drug Metab Dispos. 2021 Dec 17;50(9):1193-210. doi: 10.1124/dmd.121.000702.
4
Drug Metabolites Potently Inhibit Renal Organic Anion Transporters, OAT1 and OAT3.
J Pharm Sci. 2021 Jan;110(1):347-353. doi: 10.1016/j.xphs.2020.09.004. Epub 2020 Sep 7.
5
Pharmacogenomics of COVID-19 therapies.
NPJ Genom Med. 2020 Aug 18;5:35. doi: 10.1038/s41525-020-00143-y. eCollection 2020.
6
Pharmacogenomics of Antibiotics.
Int J Mol Sci. 2020 Aug 19;21(17):5975. doi: 10.3390/ijms21175975.
7
Regulation of organic anion transporters: Role in physiology, pathophysiology, and drug elimination.
Pharmacol Ther. 2021 Jan;217:107647. doi: 10.1016/j.pharmthera.2020.107647. Epub 2020 Aug 3.
8
Overview of organic anion transporters and organic anion transporter polypeptides and their roles in the liver.
World J Clin Cases. 2019 Dec 6;7(23):3915-3933. doi: 10.12998/wjcc.v7.i23.3915.
9
The genetic landscape of the human solute carrier (SLC) transporter superfamily.
Hum Genet. 2019 Dec;138(11-12):1359-1377. doi: 10.1007/s00439-019-02081-x. Epub 2019 Nov 2.

本文引用的文献

1
Renal transporters in drug development.
Annu Rev Pharmacol Toxicol. 2013;53:503-29. doi: 10.1146/annurev-pharmtox-011112-140317. Epub 2012 Nov 8.
2
An integrated map of genetic variation from 1,092 human genomes.
Nature. 2012 Nov 1;491(7422):56-65. doi: 10.1038/nature11632.
3
BDDCS applied to over 900 drugs.
AAPS J. 2011 Dec;13(4):519-47. doi: 10.1208/s12248-011-9290-9. Epub 2011 Aug 5.
6
Genetic variants of human organic anion transporter 4 demonstrate altered transport of endogenous substrates.
Am J Physiol Renal Physiol. 2010 Oct;299(4):F767-75. doi: 10.1152/ajprenal.00312.2010. Epub 2010 Jul 28.
7
Renal secretion of uric acid by organic anion transporter 2 (OAT2/SLC22A7) in human.
Biol Pharm Bull. 2010;33(3):498-503. doi: 10.1248/bpb.33.498.
8
Effect of genetic variation in the organic cation transporter 2 on the renal elimination of metformin.
Pharmacogenet Genomics. 2009 Jul;19(7):497-504. doi: 10.1097/FPC.0b013e32832cc7e9.
9
Plasma and peritoneal concentration following continuous infusion of cefotaxime in patients with secondary peritonitis.
J Antimicrob Chemother. 2009 Mar;63(3):564-7. doi: 10.1093/jac/dkn522. Epub 2009 Jan 23.
10
Evaluation of the nonparametric estimation method in NONMEM VI.
Eur J Pharm Sci. 2009 Apr 11;37(1):27-35. doi: 10.1016/j.ejps.2008.12.014. Epub 2008 Dec 30.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验